{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:46:44Z","timestamp":1762660004238},"reference-count":10,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2020,12,31]]},"DOI":"10.5582\/bst.2020.03443","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T22:06:05Z","timestamp":1609020365000},"page":"467-468","source":"Crossref","is-referenced-by-count":5,"title":["Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?"],"prefix":"10.5582","volume":"14","author":[{"given":"Masashi","family":"Ohe","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houman","family":"Goudarzi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy. 2020; 40:487-488.","DOI":"10.1002\/phar.2395"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Mosquera-Sulbaran JA, Hern\u00e1ndez-Fonseca H. Tetracycline and viruses: a possible treatment for COVID-19? Arch Virol. 2020:1-7. doi: 10.1007\/s00705-020-04860-8","DOI":"10.1007\/s00705-020-04860-8"},{"key":"3","unstructured":"3. Zhao TY, Patankar NA. Tetracycline as an inhibitor to the coronavirus SARS-CoV-2. https:\/\/arxiv.org\/abs\/2008.06034"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Yates PA, Newman SA, Oshry LJ, Glassman RH, Leone AM, Reichel E. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis. 2020; 14:1753466620951053. doi: 10.1177\/1753466620951053.","DOI":"10.1177\/1753466620951053"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb Al. Macrolides and COVID-19: An optimum premise. Biomed Biotechnol Res J 2020;4:189-192.","DOI":"10.4103\/bbrj.bbrj_103_20"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gautret P, Lagier JC, Parola P, <i>et al<\/i>. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56:105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Huang WH, Teng LC, Yeh TK, <i>et al<\/i>. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. J Microbiol Immunol Infect. 2020; 53:481-484.","DOI":"10.1016\/j.jmii.2020.02.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 <i>in vitro<\/i>. Antiviral Res. 2020; 178:104787.","DOI":"10.1016\/j.antiviral.2020.104787"},{"key":"9","unstructured":"9. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2020; S1201-9712(20)32506-6."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.26.20219345v1?rss=1%22","DOI":"10.22578\/IJMS.19.1.14"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/6\/14_2020.03443\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:15:13Z","timestamp":1697447713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/14\/6\/14_2020.03443\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2020.03443","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}